Search results for "Carcinoma"

showing 10 items of 3529 documents

Exosomal miRNA analysis in Non-Small Cell Lung Cancer (NSCLC) patients' plasma through qPCR : a feasible liquid biopsy tool

2016

Abstract: The discovery of alterations in the EGFR and ALK genes, amongst others, in NSCLC has driven the development of targeted-drug therapy using selective tyrosine kinase inhibitors (TKIs). To optimize the use of these TKIs, the discovery of new biomarkers for early detection and disease progression is mandatory. These plasma-isolated exosomes can be used as a non-invasive and repeatable way for the detection and followup of these biomarkers. One ml of plasma from 12 NSCLC patients, with different mutations and treatments (and 6 healthy donors as controls), were used as exosome sources. After RNAse treatment, in order to degrade circulating miRNAs, the exosomes were isolated with a comm…

0301 basic medicinePathologyLung NeoplasmsImmunology and Microbiology (all)General Chemical EngineeringBiopsynon-small cell lung cancer (NSCLC)NSCLCExosomes0302 clinical medicineCarcinoma Non-Small-Cell LungChemical Engineering (all)CancerGeneral NeuroscienceMicroRNAReal-time polymerase chain reaction030220 oncology & carcinogenesisBiomarker (medicine)MedicineEndopeptidase KCase-Control StudieEngineering sciences. TechnologyHumanmedicine.medical_specialtyReal-Time Polymerase Chain ReactionExosomeGeneral Biochemistry Genetics and Molecular BiologyRibonucleaseIssue 11103 medical and health sciencesRibonucleasesmicroRNAmedicineBiomarkers TumorHumansLiquid biopsymiRNANeuroscience (all)Biochemistry Genetics and Molecular Biology (all)Liquid biopsyGeneral Immunology and Microbiologybusiness.industryCancerBiomarkermedicine.diseaseMicrovesiclesExosomeLung NeoplasmMicroRNAs030104 developmental biologyCase-Control StudiesCancer researchReagent Kits DiagnosticbusinessJournal of visualized experiments
researchProduct

Gene Expression (mRNA) Markers for Differentiating between Malignant and Benign Follicular Thyroid Tumours

2017

Distinguishing between follicular thyroid cancer (FTC) and follicular thyroid adenoma (FTA) constitutes a long-standing diagnostic problem resulting in equivocal histopathological diagnoses. There is therefore a need for additional molecular markers. To identify molecular differences between FTC and FTA, we analyzed the gene expression microarray data of 52 follicular neoplasms. We also performed a meta-analysis involving 14 studies employing high throughput methods (365 follicular neoplasms analyzed). Based on these two analyses, we selected 18 genes differentially expressed between FTA and FTC. We validated them by quantitative real-time polymerase chain reaction (qRT-PCR) in an independe…

0301 basic medicinePathologyMicroarrayThyroid Glandlaw.inventionlawFollicular phaseGene expressionAdenocarcinoma Follicularfollicular thyroid adenoma; follicular thyroid cancer; gene expression; microarray; meta-analysisSpectroscopyPolymerase chain reactionOligonucleotide Array Sequence Analysisfollicular thyroid cancerGeneral MedicineCANCERComputer Science ApplicationsGene Expression Regulation NeoplasticCARCINOMASFUSION ONCOGENEmicroarrayNEOPLASMSmedicine.medical_specialtyMOLECULAR MARKERSASPIRATIONBiologyCatalysisCLASSIFICATIONArticleInorganic Chemistry03 medical and health sciencesNODULESADENOMASmedicineBiomarkers TumorHumansRNA MessengerThyroid NeoplasmsPhysical and Theoretical ChemistryFollicular thyroid cancerMolecular BiologyGeneGene Expression ProfilingOrganic ChemistryThyroid adenomaACVRL1medicine.diseaseMODELmeta-analysis030104 developmental biologyfollicular thyroid adenomaMutationgene expressionInternational Journal of Molecular Sciences
researchProduct

Pivotal roles of glycogen synthase-3 in hepatocellular carcinoma

2017

Hepatocellular carcinoma (HCC) is one of the most common cancers in the world, and represents the second most frequently cancer and third most common cause of death from cancer worldwide. At advanced stage, HCC is a highly aggressive tumor with a poor prognosis and with very limited response to common therapies. Therefore, there is still the need for new effective and well-tolerated therapeutic strategies. Molecular-targeted therapies hold promise for HCC treatment. One promising molecular target is the multifunctional serine/threonine kinase glycogen synthase kinase 3 (GSK-3). The roles of GSK-3β in HCC remain controversial, several studies suggested a possible role of GSK-3β as a tumor …

0301 basic medicinePathologymedicine.medical_specialtyCancer ResearchCarcinoma HepatocellularEpithelial-Mesenchymal TransitionTumor suppressor geneAntineoplastic Agentsmacromolecular substancesBiologyMetastasisGlycogen Synthase Kinase 303 medical and health sciencesWnt0302 clinical medicineGeneticTransforming Growth Factor betaGSK-3GeneticsmedicineHumansHedgehog ProteinsMolecular Targeted TherapyInsulin-Like Growth Factor IHCCIGFβ-cateninGlycogen synthaseHedgehogMolecular Biologybeta CateninGSK-3Glycogen Synthase Kinase 3 betaReceptors NotchLiver NeoplasmsWnt signaling pathwayCancermedicine.diseaseSurvival Analysisdigestive system diseasesGene Expression Regulation Neoplastic030104 developmental biology030220 oncology & carcinogenesisHepatocellular carcinomabiology.proteinCancer researchMolecular MedicineHedgehogSignal Transduction
researchProduct

PBRM1 loss is a late event during the development of cholangiocarcinoma

2017

Aims: Somatic mutations in genes encoding chromatin remodellers have been reported recently in several cancer types, including approximately half of cholangiocarcinomas. One of the most commonly mutated chromatin remodellers in cholangiocarcinoma is the Polybromo-1 (PBRM1) gene located on chromosome 3p21, which encodes a subunit of the SWI/SNF complex. The aim of this study was to determine the timing of PBRM1 mutations in biliary carcinogenesis. Methods and results: In order to accomplish this goal, we used immunohistochemistry to assess PBRM1 protein expression in a series of precursor lesions and invasive biliary carcinomas. Previous studies have correlated loss of protein expression on …

0301 basic medicinePathologymedicine.medical_specialtyHistologyBilIN; PBRM1; biliary dysplasia; cholangiocarcinoma; chromatin remodellingchromatin remodellingKaplan-Meier EstimateBiologymedicine.disease_causeArticleBilIN; PBRM1; biliary dysplasia; cholangiocarcinoma; chromatin remodelingChromatin remodelingchromatin remodelingPathology and Forensic MedicinePBRM1PBRM103 medical and health scienceschemistry.chemical_compound0302 clinical medicinemedicineHumansBilinIntrahepatic CholangiocarcinomaProportional Hazards ModelsBilINMutationNuclear ProteinsCancerGeneral MedicinePrognosismedicine.diseaseChromatinDNA-Binding Proteinsbiliary dysplasiaCell Transformation Neoplastic030104 developmental biologyBile Duct Neoplasmschemistry030220 oncology & carcinogenesisMutationCarcinogenesischolangiocarcinomaTranscription Factors
researchProduct

Glypican-3 and Hep Par-1 are Useful Biomarkers in the Cytologic Assessment of Ascites.

2018

Till date, the utility of cytologic assessment of ascites for the identification of hepatocellular carcinoma (HCC) cells is still debated and the usefulness of immunocytochemistry for glypican-3 (GPC3) and Hep Par-1 in this setting has not been reported. Liquid-based cytology of ascitic fluid of 28 cirrhotic patients was performed and the spots obtained were stained with hematoxylin and eosin, papanicolau, and with GPC3 and Hep Par-1 antibodies. GPC3 and Hep Par-1 antibodies stained positively the atypical cells in the ascites of 2 patients with HCC showing an exophytic growth pattern. The specimens of the patients with nonexophytic HCC, other non-HCC cancers, or cirrhosis stained negativel…

0301 basic medicinePathologymedicine.medical_specialtyHistologyCirrhosisCarcinoma HepatocellularH&E stainneoplastic asciteGlypican 3EpitheliumPathology and Forensic Medicineperitoneal effusionDiagnosis Differential03 medical and health sciencesimmunocytochemistry0302 clinical medicineGlypicansCytologyAscitesCarcinomaMedicineHumansProspective StudiesHCCneoplasmsReceptors Eph Familybusiness.industryLiver NeoplasmsAsciteshepatocellular carcinomamedicine.diseaseFibrosisImmunohistochemistryglypican-3digestive system diseasesMedical Laboratory Technology030104 developmental biologyLiver030220 oncology & carcinogenesisHepatocellular carcinomaImmunohistochemistrymedicine.symptomHep Par-1businessApplied immunohistochemistrymolecular morphology : AIMM
researchProduct

Pulmonary Adenocarcinoma With Enteric Differentiation: Immunohistochemistry and Molecular Morphology

2018

Pulmonary adenocarcinoma with enteric differentiation (PAED) is a rare subtype of lung adenocarcinoma recently recognized in the WHO classification. It is defined as an adenocarcinoma in which the enteric component exceeds 50% and have to show the expression of at least 1 immunohistochemical marker of enteric differentiation. Although the definition of this tumor type is very important, above all in the differential diagnosis between a primary lung tumor and a metastasis of colorectal adenocarcinoma, this cancer still lacks a distinctive immunohistochemical and molecular signature. We recruited the largest series in the literature of PAEDs according to the morphology and the positivity for …

0301 basic medicinePathologymedicine.medical_specialtyLung NeoplasmsHistologyintestinal-type adenocarcinomaCellular differentiationDNA Mutational AnalysisThyroid Nuclear Factor 1AdenocarcinomaBiologymedicine.disease_causePathology and Forensic MedicineMetastasisDiagnosis DifferentialProto-Oncogene Proteins p21(ras)03 medical and health sciences0302 clinical medicineKRASBiomarkers TumormedicineHumansCDX2 Transcription FactorPathology Molecularenteric lung adenocarcinoma intestinal-type adenocarcinoma CDX-2 CDX2 KRASLungKeratin-7entericCancerCell DifferentiationPulmonary adenocarcinoma with enteric differentiation (PAED)lung adenocarcinomamedicine.diseaseCDX-2ImmunohistochemistryMedical Laboratory Technology030104 developmental biologymedicine.anatomical_structureCDX2Alveolar Epithelial Cells030220 oncology & carcinogenesisMutationAdenocarcinomaImmunohistochemistryKRASDifferential diagnosisColorectal Neoplasms
researchProduct

Tumor infiltration by Tbet+ effector T cells and CD20+ B cells is associated with survival in gastric cancer patients

2016

International audience; Tumor-infiltrating T and B lymphocytes could have the potential to affect cancer prognosis. The objective of this study was to investigate the prognostic significance of tumor infiltration by CD8 and CD4 T cells, and B lymphocytes in patients with localized gastric cancer. In a retrospective cohort of 82 patients with localized gastric cancer and treated by surgery we quantitatively assessed by immunohistochemistry on surgical specimen, immune infiltrates of IL-17(+), CD8(+), Foxp3(+), Tbet(+) T cells and CD20(+) B cells both in the tumor core and at the invasive margin via immunohistochemical analyses of surgical specimens. We observed that CD8(+) and IL17(+) T-cell…

0301 basic medicinePathologymedicine.medical_specialtyStromal cellImmune contextureImmunologyB-cellsOvarian-cancer[SDV.CAN]Life Sciences [q-bio]/CancerExpressionFavorable prognosisT-bet[ SDV.CAN ] Life Sciences [q-bio]/Cancerhistology03 medical and health sciencesLong-term survival0302 clinical medicineImmune systemhuman tumorsmedicineImmunology and Allergy[ SDV.IMM ] Life Sciences [q-bio]/ImmunologyLymphocytesB cellOriginal ResearchCD20B cellsbiologybusiness.industrygastric cancerCarcinomaFOXP3medicine.disease3. Good health030104 developmental biologymedicine.anatomical_structureOncology030220 oncology & carcinogenesisbiology.protein[SDV.IMM]Life Sciences [q-bio]/ImmunologyprognosisbusinessOvarian cancerTertiary lymphoid structuresInfiltration (medical)Lung-cancerCD8
researchProduct

Identification of a tumor-reactive T-cell repertoire in the immune infiltrate of patients with resectable pancreatic ductal adenocarcinoma

2016

The devastating prognosis of patients with resectable pancreatic ductal adenocarcinoma (PDA) presents an urgent need for the development of therapeutic strategies targeting disseminated tumor cells. Until now, T-cell therapy has been scarcely pursued in PDA, due to the prevailing view that it represents a poorly immunogenic tumor.We systematically analyzed T-cell infiltrates in tumor biopsies from 127 patients with resectable PDA by means of immunohistochemistry, flow cytometry, T-cell receptor (TCR) deep-sequencing and functional analysis ofProminent T-cell infiltrates, as well as tertiary lymphoid structures harboring proliferating T-cells, were detected in the vast majority of biopsies f…

0301 basic medicinePathologymedicine.medical_specialtyT cell repertoirePancreatic ductal adenocarcinomaTertiary Lymphoid StructuresTumor-infiltrating lymphocyteseducationImmunologyBiology03 medical and health sciences030104 developmental biology0302 clinical medicineOncology030220 oncology & carcinogenesisMIATA Compliant Research PapermedicineImmunology and AllergyImmune infiltrateOncoImmunology
researchProduct

A case report of Muir-Torre syndrome in a woman with breast cancer and MSI-Low skin squamous cell carcinoma.

2017

IF 1.590; International audience; Background: The tumor spectrum in the Lynch syndrome is well defined, comprising an increased risk of developing colonic and extracolonic malignancies. Muir-Torre syndrome is a variant with a higher risk of skin disease. Patients have been described carrying mutations in the mismatch repair genes and presenting tumors with unusual histology or affected organ not part of the Lynch syndrome spectrum. Hence, the real link between Lynch syndrome, or Muir-Torre syndrome, and these tumors remains difficult to assess.Case presentation: We present the case of a 45-year-old-woman, diagnosed with breast cancer at 39 years of age and skin squamous cell carcinoma (SCC)…

0301 basic medicinePathologymedicine.medical_specialtycongenital hereditary and neonatal diseases and abnormalitieslcsh:QH426-470Case Report[SDV.CAN]Life Sciences [q-bio]/CancerMLH1lcsh:RC254-282Sebaceous adenoma[ SDV.CAN ] Life Sciences [q-bio]/Cancer03 medical and health sciences0302 clinical medicineSebaceous adenomaBreast cancerMuir–Torre syndromeSquamous cell carcinomaPMS2Skin Squamous Cell CarcinomaMedicineneoplasmsGenetics (clinical)MSIbusiness.industryMicrosatellite instabilitynutritional and metabolic diseasesMuir-Torre syndromeMSI-Llcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseaseMMRLynch syndromedigestive system diseases3. Good healthMSH2lcsh:Genetics030104 developmental biologyLynch syndromeOncologyMSH2030220 oncology & carcinogenesisCancer researchbusiness
researchProduct

TTF-1/p63-Positive Poorly Differentiated NSCLC: A Histogenetic Hypothesis from the Basal Reserve Cell of the Terminal Respiratory Unit

2020

TTF-1 is expressed in the alveolar epithelium and in the basal cells of distal terminal bronchioles. It is considered the most sensitive and specific marker to define the adenocarcinoma arising from the terminal respiratory unit (TRU). TTF-1, CK7, CK5/6, p63 and p40 are useful for typifying the majority of non-small-cell lung cancers, with TTF and CK7 being typically expressed in adenocarcinomas and the latter three being expressed in squamous cell carcinoma. As tumors with coexpression of both TTF-1 and p63 in the same cells are rare, we describe different cases that coexpress them, suggesting a histogenetic hypothesis of their origin. We report 10 cases of poorly differentiated non-small-…

0301 basic medicinePathologymedicine.medical_specialtyendocrine systemAlveolar EpitheliumClinical Biochemistryhistogenetic hypothesisBiologyNSCLCArticle03 medical and health sciencesBasal (phylogenetics)0302 clinical medicineterminal respiratory unitmedicineCarcinomabasal reserve cellslcsh:R5-920p63LungBasal reserve cellCancerrespiratory systemmedicine.disease030104 developmental biologymedicine.anatomical_structurenon-small-cell lung cancerTTF-1030220 oncology & carcinogenesisAdenocarcinomaImmunohistochemistrylcsh:Medicine (General)ImmunostainingHistogenetic hypothesiDiagnostics
researchProduct